KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Zacks2024-12-20

Krystal Biotech KRYS announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492025121?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2NHx6klCutBjAlMNJEM7HQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b5aeac1c53d022d48463312844fb1baf","is_english":true,"pubTime":"2024-12-20 00:08","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492025121","market":"us","top_or_hot":-1,"title":"KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707","media":"Zacks","content":"<div>\n<p>Krystal Biotech KRYS announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung...</p>\n\n<a href=\"https://finance.yahoo.com/news/krys-reports-upbeat-initial-data-160800963.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 00:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/krys-reports-upbeat-initial-data-160800963.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Krystal Biotech KRYS announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung...</p>\n\n<a href=\"https://finance.yahoo.com/news/krys-reports-upbeat-initial-data-160800963.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SPRO","symbol_name":"Spero Therapeutics Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/krys-reports-upbeat-initial-data-160800963.html","article_id":"2492025121","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2NHx6klCutBjAlMNJEM7HQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b5aeac1c53d022d48463312844fb1baf"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492025121","pubTimestamp":1734624480,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Krystal BiotechKRYS announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.The phase I/II KYANITE-1 study is evaluating the safety, tolerability and tumor response  of inhaled KB707 as a monotherapy in 37 patients with malignant lesions in the lung. Out of the total enrolled patient population, 17 were diagnosed with advanced non-small cell lung cancer . Two doses of KB707  were evaluated during the dose-escalation phase of the KYANITE-1 study, following which 109PFU was selected for dose expansion.Results showed that patients treated with inhaled KB707 demonstrated early evidence of monotherapy activity with the most therapeutic benefit observed in advanced NSCLC patients, who have progressed after standard-of-care treatments.In the past three months, shares of Krystal Biotech have lost 14.9% compared with theindustry’s 13.3% decline.KB707 is also being develope","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SPRO":"Spero Therapeutics Inc.","CSTL":"Castle Biosciences, Inc.","CTMX":"CytomX","BK4139":"生物科技","BK4196":"保健护理服务","KRYS":"Krystal Biotech Inc."},"translate_title":"KRYS报告KB707肺癌研究的乐观初始数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTMX":1,"KRYS":1,"SPRO":1,"CSTL":0.9},"content_text":"Krystal Biotech KRYS announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.\nThe phase I/II KYANITE-1 study is evaluating the safety, tolerability and tumor response (measured using RECIST v1.1 criteria) of inhaled KB707 as a monotherapy in 37 patients with malignant lesions in the lung. Out of the total enrolled patient population, 17 were diagnosed with advanced non-small cell lung cancer (NSCLC). Two doses of KB707 (108 PFU or 109 PFU) were evaluated during the dose-escalation phase of the KYANITE-1 study, following which 109 PFU was selected for dose expansion.\nResults showed that patients treated with inhaled KB707 demonstrated early evidence of monotherapy activity with the most therapeutic benefit observed in advanced NSCLC patients, who have progressed after standard-of-care treatments.\nIn the past three months, shares of Krystal Biotech have lost 14.9% compared with the industry’s 13.3% decline.\nImage Source: Zacks Investment Research\nMore on KRYS’Development of KB707 for Lung Cancer\nOut of the 17 NSCLC patients treated with inhaled KB707 in Krystal Biotech’s KYANITE-1 study, 11 were evaluable for response with at least one radiographic scan and RECIST v1.1 evaluation as of data cut-off on Dec. 6, 2024.\nThe analyzed patients had undergone extensive treatment, with a median of four prior therapy lines, including at least one immunotherapy. In this NSCLC cohort, an overall response rate (ORR) of 27% was observed, with three partial responses. The disease control rate (DCR) reached 73%, with seven out of 11 patients continuing treatment. Treatment durations ranged from 10.3 to 33.3 weeks as of the data cut-off.\nAdditionally, Krystal Biotech reported that treatment with inhaled KB707 showed promising results outside the lungs, with notable responses in lung lesions. Among the 11 evaluable NSCLC patients, the ORR in target lung lesions specifically was 36%, including three partial responses and one complete response, while DCR was 82%. Despite being early, management believes that the observed monotherapy activity with inhaled KB707 supports the potential of KRYS’ HSV-1 platform to safely and repeatedly deliver functional genetic material to the lung and impact the course of the disease.\nEncouraged by positive initial monotherapy results, Krystal Biotech has updated the KYANITE-1 protocol to include two new cohorts studying inhaled KB707 in combination with anti-PD-1 therapy alone or with chemotherapy for advanced NSCLC. Patient enrollment in these combination cohorts has not yet begun. The company expects to disclose detailed and updated results of KYANITE-1 at future medical conferences.\nKB707 is also being developed as an intratumoral injection, which is being developed in a phase I/II OPAL-1 study to pre-treated patients with locally advanced or metastatic solid tumors. A data readout from this study is expected soon.\n\nKrystal Biotech, Inc. Price and Consensus\n\nKrystal Biotech, Inc. price-consensus-chart | Krystal Biotech, Inc. Quote\n\nKRYS’ Zacks Rank & Stocks to Consider\nKrystal Biotech currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and Spero Therapeutics SPRO, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past three months, shares of Castle Biosciences have lost 15.7%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.\nIn the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. In the past three months, CTMX stock has lost 10.9%.\nCytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past three months, Spero’s shares have lost 25.2%.\nSPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nKrystal Biotech, Inc. (KRYS) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492025121"}